A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0
|
作者：
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Zhu, Mojun
Wittenberger, Kathleen
Csiszovszki, Zsolt
Somogyi, Eszter
Lorincz, Orsolya
Molnar, Levente
Toth, Jozsef
Youssoufian, Hagop
Toke, Eniko Rita
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Med Oncol, Phoenix, AZ USA
[3] Mayo Clin Florida, Jacksonville, FL USA
[4] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN USA
[5] TreosBio, Veszprem, Hungary
[6] Treos Bio, Veszprem, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3594
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
    Liu, Rui
    Ji, Zhi
    Wang, Xia
    Zhu, Lila
    Xin, Jiaqi
    Ma, Lijun
    Zhang, Jiayu
    Ge, Shaohua
    Zhang, Le
    Yang, Yuchong
    Ning, Tao
    Bai, Ming
    Duan, Jingjing
    Wang, Feixue
    Sun, Yansha
    Li, Hongli
    Deng, Ting
    Ba, Yi
    Hao, Jihui
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [42] Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
    Zhao, Wensi
    Lei, Jun
    Ke, Shaobo
    Chen, Yuan
    Xiao, Jiping
    Tang, Ze
    Wang, Li
    Ren, Yiping
    Alnaggar, Mohammed
    Qiu, Hu
    Shi, Wei
    Yin, Lei
    Chen, Yongshun
    ECLINICALMEDICINE, 2023, 66
  • [43] Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
    Bendell, Johanna C.
    Kopetz, Scott
    Middleton, Mark R.
    Eves, P. Taylor
    Bozon, Viviana
    Boyd, Adam P.
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [44] Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.
    Liu, Tianshu
    Yang, Mudan
    Li, Jin
    Pan, Yueyin
    Yuan, Ying
    Yi, Shanyong
    Wang, Junsheng
    Cheng, Ying
    Feng, Jifeng
    Gao, Shegan
    Wang, Xicheng
    Qu, Song
    Zhang, Xizhi
    Lu, Jin
    Xiu, Peng
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)
    Zhongzhen, G
    Fengyi, F
    Xiaoqing, L
    Yajie, W
    Baoming, Y
    Qionghua, Z
    Lin, S
    Shiying, Y
    Huaqing, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 303S - 303S
  • [46] A phase 3 open-label, randomized, multicenter study of Imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer
    Huhn, Richard Dale
    Lowe, Jamie
    Grady, Michele
    Taitt, Corina Candiani
    Gargano, Michele Anne
    Braun, Ada H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [47] A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab in Patients with KRAS Wild Type Metastatic Colorectal Cancer
    Huhn, R.
    Lowe, J.
    Grady, M.
    Taitt, C.
    Braun, A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [48] Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
    Siena, Salvatore
    Van Cutsem, Eric
    Li, Mingyu
    Jungnelius, Ulf
    Romano, Alfredo
    Beck, Robert
    Bencardino, Katia
    Elena Elez, Maria
    Prenen, Hans
    Sanchis, Mireia
    Sartore-Bianchi, Andrea
    Tejpar, Sabine
    Gandhi, Anita
    Shi, Tao
    Tabernero, Josep
    PLOS ONE, 2013, 8 (11):
  • [49] Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC)
    Hollebecque, Antoine
    Calvo, Aitana
    Andre, Thierry
    Argiles, Guillem
    Cervantes, Andres
    Leger, Catherine
    Valette, Aude
    Amellal, Nadia
    Fougeray, Ronan
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [50] A phase 2, multicenter, open-label study of AlloStim in-situ cancer vaccine immunotherapy as 3L therapy in MSS/pMMR metastatic colorectal cancer.
    Lausoontornsiri, Wirote
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS317 - TPS317
12345